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Abstract
Introduction: Semaphorin 3A (sema3A) and neuropilin-1 (NP-1) play a regulatory role in immune responses and
have a demonstrated effect on the course of collagen induced arthritis. This study was undertaken to evaluate the
role of sema3A and NP-1 in the pathogenesis of systemic lupus erythematosus (SLE) and the specific effect of
sema3A on the auto-reactive properties of B cells in SLE patients.
Methods: Thirty two SLE and 24 rheumatoid arthritis (RA) patients were assessed and compared with 40 normal
individuals. Sema3A serum levels were measured and correlated with SLE disease activity. The in vitro effect of
sema3A in reducing Toll-like receptor 9 (TLR-9) expression in B cells of SLE patients was evaluated.
Results: Sema3A serum levels in SLE patients were found to be significantly lower than in RA patients (55.04 ±
16.30 ng/ml versus 65.54 ± 14.82 ng/ml, P = 0.018) and lower yet than in normal individuals (55.04 ± 16.30 ng/ml
versus 74.41 ± 17.60 ng/ml, P < 0.0001). Altered serum sema3A levels were found to be in inverse correlation with
SLE disease activity, mainly with renal damage. The expression of both sema3A and NP-1 on B cells from SLE
patients was significantly different in comparison with normal healthy individuals. Finally, when sema3A was co-
cultured with cytosine-phosphodiester-guanine oligodeoxynucleotides (CpG-ODN)-stimulated B cells of SLE
patients, their TLR-9 expression was significantly reduced, by almost 50% (P = 0.001).
Conclusions: This is the first study in which a reduced serum level of sema3A was found in association with SLE
disease activity. It also raises the possibility that sema3A may have a regulatory function in SLE.
Introduction
Semaphorins are a large family (classified into eight sub-
classes) of secreted and membrane bound proteins ori-
ginally discovered in the nervous system, which are
involved in repulsive axon guidance during nervous sys-
tem development [1-3]. They relate to two families of
receptors: the neuropilins (NP-1 and NP-2) as the pri-
mary ligand binding sites and plexins, as the signal-
transducing components [4-6]. Recent data have pointed
to the involvement of NP-1 and semaphorins in the reg-
ulation of the immune system, and are thus denoted as
‘immune semaphorins’ [7-9].
Semaphorin 3A (sema3A), a secreted member of this
family, is well reported as a potent immuno-regulator dur-
ing all immune response stages, namely, the early initia-
tion and the late phase of inflammatory processes [10].
The expression of sema3A, NP-1, NP-2, and plexins were
found to be increased on differentiating macrophages and
on activated T cells, suggesting that they have a role in
modulating inflammatory conditions [11]. The addition of
sema3A to dendritic cell (DC)/T cell co-cultures signifi-
cantly inhibited allogeneic T cell proliferation. Moreover,
neutralization by blocking antibodies against endogenous
sema3A resulted in a profound increase in T cell prolifera-
tion [12]. Both NP-1 and sema3A expression was recog-
nized on T regulatory cells as a suppressive marker,
contributing to the regulatory properties of these cells
[13-16]. In another study, the known immunosuppressive
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function of bone marrow mesenchymal stem cells (MSCs)
was attributed in part to their ability to secrete sema3A
which, by binding to NP-1, was found to inhibit T cell
proliferation [17]. Becoming a frontier player in the regula-
tion of immune responses and the maintenance of self-tol-
erance, sema3A should be expected to be involved in the
pathogenesis of many autoimmune diseases [18,19]. The
study by Catalano [20] was the first to report on the defec-
tive expression of sema3A in CD4 T cells derived from
patients with rheumatoid arthritis (RA). In this study,
sema3A was shown to enhance the suppressive ability of
CD4+NP-1+ T cells by increasing their IL-10 expression
and their regulatory function on effector CD4+ T cells.
Their altered expression on T cells was shown to correlate
with the progression of RA. In consideration of the above,
we initiated this current study to assess the possible role
of sema3A in systemic lupus erythematosus (SLE), namely
to measure its serum level in SLE patients and assess
whether this level correlates with disease status. In addi-
tion, we sought to assess the possible in vitro immuno-
modulatory effect of sema3A on B cells of SLE patients.
Materials and methods
Patient population
Serum samples from 32 SLE patients and from 24 RA
patients (disease control) who were followed in the out-
patient clinics of an academic community hospital, and
from 40 healthy controls, were all analyzed for sema3A
serum level. SLE patients were evaluated for disease
activity by using the Systemic Lupus Erythematosus Dis-
ease Activity Index (SLEDAI) [21]. All SLE patients
were scored mild to severe with a SLEDAI ranging
between 4 and 24. Of relevance, blood was drawn before
any steroid pulse or increase of cytotoxic therapy was
initiated when severity of disease activity required it.
Informed consent was obtained, and the study was
approved by the local Helsinki committee. Table 1 sum-
marizes the clinical and laboratory characteristics of all
SLE patients included in this study. Seven patients with
mild disease were treated only with hydroxychloroquine
(HCQ), another eight patients were treated with add-on
2.5 to 5 mg of prednisone, and 17 patients, considered
having moderate to severe disease, received low to mod-
erate daily doses of cytotoxic therapy. Nine patients suf-
fered from renal involvement, 19 patients were anti-ds
DNA antibody positive and 17 had anti-cardiolipin anti-
bodies of moderate to high titers.
Semaphorin 3A serum level
The measurement of sema3A serum level was con-
ducted using a commercial ELISA kit (USCNK Life
Science, Wuhan, P.R.China) according to the manufac-
turer’s instructions. The serum samples were stored at
-20° until ELISA evaluation.
Clinical correlations
Results of the SLE patients’ serum sema3A levels were
correlated with their SLEDAI score, renal involvement
and laboratory serologic studies including anti-
dsDNA, anti-cardiolipin antibodies and C3-C4 serum
levels.
The expression of Semaphorin 3A and NP-1 on CD25high
B cells
The expression of sema3A on CD19/CD25high B cells
from healthy controls and SLE patients was assessed by









1 16 44 + + L L HCQ; P
2 14 32 + + + L L HCQ; P
3 3 82 N N HCQ
4 4 63 N L P
5 4 69 + N N HCQ; P; AZA
6 4 51 + N N HCQ;
Atabrin
7 5 69 + N L HCQ; P
8 8 53 N L HCQ; P; AZA
9 6 79 + + L L HCQ; P; AZA
10 12 44 N L HCQ; P; AZA
11 6 65 N N HCQ; P
12 9 48 + N L HCQ; P; AZA
13 6 65 + + L L HCQ; P; AZA
14 3 76 N L HCQ; P
15 12 42 + + N L HCQ; P; AZA
16 8 64 + + L L HCQ; P;
17 18 38 + + + L L HCQ; P; AZA
18 18 33 + + + L L HCQ; P;
MTX; IVIg
19 4 68 + N L HCQ; P; AZA
20 6 55 N N HCQ; P
21 6 60 + + N L HCQ; P
22 24 20 + + + L L HCQ; P;
MTX; IVIg
23 5 70 + N N HCQ; P
24 10 50 + + + L L HCQ; P; AZA
25 13 36 + + + L L HCQ; P;
26 4 65 + N N HCQ;
27 26 26 + + + L L HCQ; P; CYC
28 6 61 N N HCQ; P; AZA
29 4 63 N N HCQ; P; AZA
30 4 59 N L HCQ
31 5 58 + + N N HCQ; P; AZA
32 20 34 + + + L L HCQ; P; CYC
a.Cal, anti-cardiolipin; a.dsDNA, anti-double-stranded DNA; AZA, azathioprine;
CYC, cyclophosphamide; F, female; HCQ, hydroxychloroquine; IVIg, intravenous
immunoglobulin; L, low; LN, lupus nephritis; M, male; MTX, Methotrexate; N,
normal; P, prednisone; Sema3A, semaphorin 3A.
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staining whole blood with monoclonal antibodies,
human anti-CD19 FITC/PE and CD25 PC5 (Immuno-
tech, Beckman-Coulter, Marseille, France), and human
anti-sema3A AlexaFluor 488 or human anti-NP1 PE
(R&D, Minneapolis, MN, USA), and evaluated using
flow cytometry software (FC500 and CXP software,
Beckman Coulter, Brea, CA, USA).
Purification of B cells
B cells were purified from peripheral blood of SLE
patients. To do so, peripheral blood mononuclear cells
(PBMCs) were isolated on Lymphoprep (Axis-Shield,
Oslo, Norway), and B lymphocytes were isolated by
positive selection using CD22 microbeads (20 μl/107
cells; Miltenyi Biotec, Bergisch Gladbach, Germany)
according to the manufacturer’s instructions, achieving
> 98% purity.
Toll-Like-Receptor 9 (TLR-9) expressions
Purified B cells, gating on memory CD19+/CD27+
(Immunotech, Beckman-Coulter, Marsellie, France) B
cells, from SLE patients were analyzed for TLR-9
expression. Condition-media from HEK293- cells, which
were infected by NSPI-CMV-FLAG lentivirus with or
without sema3A cDNA, as previously described [22],
was added to purified B cells activated by, cytosine-
phosphodiester-guanine oligodeoxynucleotides (ODN-
CpG) and incubated for 60 hours. After incubation, cells
were fixed and permeabilized using a commercial kit
(’Fix and Perm’, Invitrogen, Carlsbad, CA, USA), accord-
ing to the manufacturer’s instructions, and analyzed for
TLR-9 expression. The staining was performed using
specific monoclonal anti-human TLR-9-PE antibody
(Imgenex, San Diego, CA, USA) and evaluated using a
FC500 flow cytometer.
Statistical analysis
Comparison of sema3A expression on B cells of SLE
patients and healthy controls was performed using the
unpaired student t-test. The correlation coefficient (r) of
clinical correlation between SLEDAI score and sema3A
levels was determined using the Pearson correlation test.
A two tailed P-value of 0.05 or less was considered to
be statistically significant.
Results
Semaphorin 3A serum level
As shown in Figure 1, the sema3A serum level was
lower in RA and SLE patients compared to healthy con-
trols. In controls, the serum level was 74.41 ± 17.60 ng/
ml whereas in SLE patients it was significantly lower
(55.04 ± 16.30 ng/ml, P < 0.0001). The sema3A level
was also low in RA patients (65.54 ± 14.82 ng/ml, P =
0.047) compared to its level in healthy controls but was
higher than that of SLE patients (P = 0.018).
Clinical correlations
Sema3A serum levels in SLE patients were evaluated in
relation to SLE disease activity determined by SLEDAI
score (including anti-dsDNA antibody). The levels were
found to be inversely correlated with disease activity (R
= -0.89, P < 0.0001) (Figure 2A). In addition, the asso-
ciation between the sema3A serum levels and the pre-
sence of lupus nephritis was evaluated: 73% of patients
with a sema3A level below 50 ng/ml had kidney involve-
ment. However, in those with sema3A levels above 50
ng/ml, only 5% had kidney involvement (Figure 2B).
Further, lower sema3A serum levels were also found in
association with the higher presence of anti-cardiolipin
antibodies; namely, when the sema3A level measured
was below 50 ng/ml, 64% of the patients were anti-car-
diolipin positive; however, with sema3A levels above 50
ng/ml, only 33% of patients were anti-cardiolipin posi-
tive (Figure 2C). Anti-beta 2 Glycoprotein1 (GPI) was
performed in all positive anti-cardiolipin positive
patients, and was found positive in only ten patients (a
too small number for a proper correlation). However,
when we looked for a possible correlation between
sema3A and the presence of thrombotic events we
found that among all anti-cardiolipin positive patients,
five developed thrombotic events (patients No. 1, 15, 22,
25, 32), all of whom had very low sema3A levels, and in
three of whom anti-beta2 GPI was also positive. In addi-
tion, a positive correlation was found between the serum
level of sema3A and C3 values (r = 0.078, P = 0.0008)
and C4 values (r = 0.523, P = 0.005) (Figure 3A and 3B).
Figure 1 Serum levels of semaphorin 3A in SLE, RA patients
and healthy controls. Sema3A serum levels were significantly
lower in SLE patients compared to those in RA patients (55.04 ±
16.30 ng/ml versus 65.54 ± 14.82 ng/ml, P = 0.018) and even lower
compared to healthy controls (55.04 ± 16.30 ng/ml versus 74.41 ±
17.60 ng/ml, P < 0.0001). RA, rheumatoid arthritis; SLE, systemic
lupus erythmatosus.
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Figure 2 Clinical correlations. (A) demonstrates the inverse correlation between sema3A serum levels in SLE patients and their SLEDAI score (R
= -0.89, P < 0.0001). (B) expresses the association between sema3A serum level and kidney involvement. As is shown, serum levels higher than
50 ng/ml are associated with a lower rate of kidney involvement, and those with higher than 50 ng/ml are associated with increased rate of
renal damage. (C) shows the association between decreased serum sema3A levels and the presence of anti-cardiolipin antibodies positivity.
Sema3A, semaphorin 3A; SLEDAI, Systemic Lupus Erythematosus Disease Activity Index.
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The expression of Semaphorin 3A and NP-1 on B cells
Sema3A protein is produced by several immune cells
such as B and T cells and activated monocytes. Being of
a fundamental role in SLE, we considered the measure-
ment of sema3A on B cells to be of high relevance.
Importantly, the main expression of sema3A was found
by us to be on CD19+CD25high B cells (mean fluores-
cence intensity (MFI: 4.3), which were previously
reported by us to be the B regulatory cells [23]. On the
other hand, sema3A was minimally expressed on CD19
+CD25low (MFI: 1.8) P = 0.001. We, therefore, decided
to assess the expression of sema3A and NP-1 on
CD25high B cells, namely, B regulatory cells. As shown
in Figure 4, the level of sema3A protein was expressed
lower on CD19+CD25high B cells from SLE patients
compared to CD19+CD25high B cells from healthy con-
trols (52.2 ± 5.8% versus 82.6 ± 6.4%, P < 0.0001,
respectively (MFI: 2.68 ± 0.09 versus 4.27 ± 0.47, P =
0.019). NP-1 expression was also found to be signifi-
cantly lower on CD25high B cells of SLE patients when
compared to that from healthy individuals (10.8 ± 3.6%
versus 15.4 ± 1.4%, P = 0.03).
Figure 3 The correlation of C3-C4 levels with sema3A serum levels. (A) demonstrates a positive correlation between sema3A serum levels
in SLE patients and C3 values (r = 0.078, P = 0.0008). (B) demonstrates a positive correlation between sema3A serum levels in SLE patients and
C4 values (r = 0.523, P = 0.005). Sema3A, semaphorin 3A; SLE, systemic lupus erythematosus.
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TLR-9 expression in B cells
The analysis of TLR-9 expression was performed on
purified B cells from SLE patients that were incubated
with or without sema3A conditioned-media. TLR-9
expression on memory B cells was significantly lower
following the incubation of B cells with sema3A, by
almost 50% (P = 0.001) compared to B cells with med-
ium only (Figure 5).
Discussion
The involvement of sema3A in regulating both in vitro
and in vivo inflammatory responses has been previously
suggested and shown to be of high relevance. The pleio-
tropic effects of sema3A have been shown to involve a
variety of cells, such as T cells, monocytes, macrophages
and endothelial cells (ECs) [24-27]. In this respect,
sema3A was shown to inhibit Th1 mediated inflamma-
tory responses in RA patients, that is, reducing the pro-
duction of pro-inflammatory cytokines such as IFN-g
and IL-17 [15,20].
This study is the first in which sema3A is shown to
play a role in the pathogenesis of SLE, that is, a role in
humoral responses, as well as a role in modulating the
autoimmune properties of B cells in SLE. Serum
sema3A levels were demonstrated to be low in SLE
patients, in negative correlation with disease activity,
renal damage and the presence of anti-cardiolipin anti-
bodies. It is thus suggested that sema3A is a candidate
to become a useful marker for SLE disease activity and
renal damage. Though of high significance, our results
on sema3A serum levels in SLE patients should be
strengthened with a larger number of patients in future
studies. In addition, sema3A serum levels should be
assessed when patients are in remission. As B cells are
the source of autoantibodies and pro-inflammatory cyto-
kine production in SLE, a correlation with sema3A
expression on B cells in any relation to these activities
was assessed. Indeed, it was found that sema3A expres-
sion as well as the expression of its receptor NP-1 was
significantly decreased on CD19/CD25high (Breg) cells
from SLE patients when compared to that on this subset
of cells of normal individuals.
The observation that sema3A expression is mainly pre-
sent on CD19+CD25high cells suggests sema3A as a
unique marker for this subset of cells. It may be specu-
lated that when sema3A expression is diminished, B cells
Figure 4 Expression of Semaphorin 3A on CD19+CD25high B cells. (A) demonstrates the MFI of CD19+CD25highSema3A+ expression on B
cells in whole blood from SLE patients compared to that of healthy controls (4.27 ± 0.47 versus 2.68 ± 0.09, P = 0.019). (B) is a representative
histogram of the lower sema3A expression on B cells from SLE patients compared to that in healthy controls. The blank histogram represents
the isotype control. MFI, mean fluorescence intensity; SLE, systemic lupus erythematosis.
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may lose their regulatory signal and escape self-tolerance
becoming auto-reactive and autoantibody producers. NP-
1 down-regulation on B cells may also contribute to the
development of B cell auto-reactivity and auto-immunity
in SLE. Indeed, earlier studies have contributed to the
understanding that NP-1 expression may be important
for regulatory responses. In this respect, NP-1 positive
CD4 T cells have been designated as CD4+CD25+Foxp3
+NP-1+ [20]. Our finding of decreased NP-1 expression,
along with decreased sema3A expression on B cells in
SLE further suggests that this defect may play an impor-
tant role in the pathogenesis of SLE. Assuming that
sema3A and NP-1 are essential for the regulatory func-
tion of B cells, one would expect to see that when their
expression on B cells is decreased, B cells may shift, to
become more pro-inflammatory rather that regulatory,
and contribute to the development of SLE. There
remains still a lack of understanding as to what causes
sema3A and NP-1 to be altered in SLE. The milieu of
increased pro-inflammatory cytokines such as IFN-g and
IL-6 may be a factor.
Further, sema3A has been reported to be important in
the induction of the apoptosis of many immune cells,
such as monocytes and macrophages, when these were
found to be resistant to Fas-induced apoptosis [28].
Therefore, when sema3A expression is altered auto-
reactive B cells escape apoptosis and survive to overpro-
duce autoantibodies, thus contributing to autoimmunity
in SLE. The association between TLR-9 expression in B
cells, especially memory B cells and the production of
IL-10 and IL-6 cytokines in SLE was previously shown
by many [29-31]. The over-expression of TLR-9 in
memory B cells was also shown to be in correlation
with anti-dsDNA antibody production. Thus, modula-
tion of TLR-9 expression has been suggested as a thera-
peutic target, aiming to reduce its expression in SLE to
be followed by a reduction of IL-10 production which
has been demonstrated to be associated with SLE dis-
ease activity. Considering sema3A to be an important
regulator in SLE, we hypothesized that co-culturing
sema3A with B cells of SLE patients could possibly
reduce TLR-9 expression. Indeed, it was demonstrated
in the present study that the addition of sema3A, in
vitro, to B cells of SLE patients, significantly reduced
ODN-CpG induced TLR-9 expression in memory B
cells, supporting sema3A as a regulator of autoimmunity
in SLE. These findings along with the observation of
sema3A being reduced in SLE patients, in correlation
with disease severity and autoimmunity, and memory B
cells being beneficially responsive to sema3A suggest
this regulatory molecule as a therapeutic agent for SLE
to be assessed in the future.
Conclusions
Sema3A is a good marker for SLE disease activity. It has
a regulatory mode of action, with proven abilities of
decreasing TLR9 expression in memory B cells of SLE
patients. In addition, sema3A is shown to enhance regu-
latory properties of B cells. Further studies will focus on
the therapeutic potential of sema3A in SLE.
Figure 5 TLR-9 expression in B cells is reduced by sema3A. The co-culture of ODN-CpG stimulated B cells from SLE patients with sema3A
reduced their TLR-9 expression by almost 50%. CpG-ODN, cytosine-phosphodiester-guanine oligodeoxynucleotides; sema3A, semaphorin 3A; SLE,
systemic lupus erythematosis; TLR-9, Toll-like receptor 9.
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